# Black Lung Disease Market

> Black Lung Disease Market Research Report By Disease Type (Simple Coal Workers’ Pneumoconiosis, Complicated Coal Workers’ Pneumoconiosis, Progressive Massive Fibrosis), By Component (Diagnostic Method, Chest X-Ray, CT Scan, Pulmonary Function Test, Other Diagnostic Methods, Treatment Type), By End Users (Hospitals, Specialty Clinics, Diagnostic Laboratories, Other End-Users) and By Region (North America, Europe, South America, Asia-Pacific, Middle East and Africa) – Growth Outlook & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 5.48%
- **2025:** USD 2.46 Billion
- **2035:** USD 4.14 Billion
- **Key Players:** Boehringer Ingelheim, GSK plc, AstraZeneca, F. Hoffmann-La Roche, Novartis, Koninklijke Philips, GE HealthCare, Siemens Healthineers

**Report ID:** MRFR/Pharma/4256-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** November 16, 2026

**URL:** https://www.marketresearchfuture.com/reports/black-lung-disease-market-5711

---

## Market Summary

## Black Lung Disease Market Summary

The global Black Lung Disease Market was valued at USD 2.46 Billion in 2025 and is projected to reach USD 2.56 Billion in 2026, rising to USD 4.14 Billion by 2035 at a CAGR of 5.48% over 2026–2035.

The period is characterized by two regulatory catalysts. The permissible exposure limit for respirable crystalline silica was reduced by half to 50 µg/m³ by the US Mine Safety and Health Administration (MSHA) in its April 2024 final rule. Coal-mine compliance is expected to commence in 2025 [1]. The black lung excise tax was made permanent at USD 1.10 per ton of underground coal by the Inflation Reduction Act, which stabilized the benefit financing that funds diagnosis and care [6].

Film-based chest radiographs that are read in isolation are being phased out of clinical practice in the Black Lung Disease Market. In contrast, [portable oxygen concentrators](https://www.marketresearchfuture.com/reports/portable-oxygen-concentrator-market-43273) are replacing stationary cylinder supplies at home, while digital radiography, low-dose CT, AI-assisted ILO classification, and connected spirometry are replacing that workflow. NIOSH's Coal Workers' Health Surveillance Program continues to provide funding for mobile screening units in Appalachia, providing vendors with a consistent public-sector consumer for digital imaging and lung-function testing [2].

In 2025, North America holds the leading position with a 38.5% share, which is based on federal surveillance, benefits adjudication, and specialist pulmonary networks. Driven by China, India, and Indonesia, the Asia-Pacific region is the fastest-growing, with a compound annual growth rate (CAGR) of 7.1% [10]. As a result, coal output remains at near-record levels. Europe's revenue ranking is third, but it maintains a 22.0% market share, which is bolstered by occupational-disease registries and silica regulations in accordance with Directive (EU) 2017/2398 [22]. The Black Lung Disease Market will shift toward long-term home-based management and earlier detection through 2035.

## Key Report Takeaways

### • By Disease Type

- Complicated Coal Workers’ Pneumoconiosis led the Black Lung Disease Market with a 41.2% share in 2025, reflecting high imaging and treatment intensity per patient.
- Simple Coal Workers’ Pneumoconiosis is the fastest-growing disease category at a 5.9% CAGR as screening coverage widens.
- Progressive Massive Fibrosis generated USD 0.55 Billion in 2025 despite a smaller patient pool.

### • By Component

- Treatment Type accounted for a 55.1% share of the Black Lung Disease Market in 2025, anchored by medication and long-term oxygen therapy.
- Diagnostic Method revenue reached USD 1.10 billion in 2025, led by chest X-ray surveillance programs.

### • By End-user

- Hospitals captured a 43.9% share of the Black Lung Disease Market in 2025, owing to inpatient management of advanced fibrosis
- Diagnostic Laboratories post the fastest end-user growth at a 6.3% CAGR as spirometry and CT reading move closer to [occupational health](https://www.marketresearchfuture.com/reports/occupational-health-market-43100) pathways

### • By Region

- North America held a 38.5% share of the Black Lung Disease Market in 2025
- Asia-Pacific is projected to grow at a 7.1% CAGR through 2035
- South America contributed USD 0.14 Billion in 2025

## Market Size and Forecast (2021–2035)

Black Lung Disease Market estimates combine bottom-up modelling of diagnosed patient pools, screening volumes and treatment uptake with top-down checks against healthcare expenditure, benefits payments and supplier revenues. Patient counts draw on NIOSH surveillance data, US Department of Labor claims statistics and national occupational-disease bulletins, while pricing reflects published reimbursement schedules and procurement data [2][5].

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Stricter dust and silica exposure rules | +1.2% | North America, Europe, Australia | Medium-term (2–4 yr) | [1][22] |
| Resurgence of advanced disease in Appalachia | +1.0% | North America | Long-term (≥4 yr) | [3][12] |
| Expanding screening in Asian coal economies | +1.1% | China, India, Indonesia | Long-term (≥4 yr) | [10] |
| Stable benefits financing | +0.7% | United States | Short-term (≤2 yr) | [6][7] |
| AI-assisted radiograph and CT reading | +0.8% | Global | Medium-term (2–4 yr) | [8][19] |
| Growth of home oxygen and portable concentrators | +0.6% | North America, Europe | Short-term (≤2 yr) | [18][21] |

### Stricter Dust and Silica Exposure Rules

MSHA's 2024 rule cut the silica limit to 50 µg/m³ and set an action level of 25 µg/m³, layered on the 2014 coal dust rule that lowered the respirable coal dust standard to 1.5 mg/m³ [1][11]. Operators must expand sampling and, for metal and non-metal mines, offer periodic medical examinations. Each new obligation creates recurring demand for chest imaging, spirometry and physician interpretation, much of it bought through occupational health contractors rather than hospitals.

### Resurgence of Advanced Disease in Appalachia

Progressive massive fibrosis, once thought nearly eliminated, has returned. A 2018 JAMA study identified 416 cases at three Virginia clinics between 2013 and 2017, the largest cluster on record [3]. Analysis of benefits claims found PMF among claimants rising sharply after 2000 [12]. Because PMF patients require frequent CT, pulmonary rehabilitation, oxygen and transplant evaluation, this resurgence lifts per-patient spending well above the average for occupational lung disease.

### Expanding Screening in Asian Coal Economies

Global coal demand hit roughly 8.77 billion tonnes in 2024, with China and India accounting for most consumption [10]. China's National Health Commission reports that pneumoconiosis remains the largest share of newly reported occupational disease cases each year. As provincial authorities enforce mandatory pre-placement and periodic examinations, hospital radiology departments and third-party labs absorb rising test volumes, making Asia-Pacific the main source of incremental diagnostic revenue.

### Stable Benefits Financing

The Black Lung Disability Trust Fund had accumulated more than USD 4 billion in debt by 2018, according to GAO, threatening program continuity [7]. Section 11121 of the Inflation Reduction Act ended the cycle of temporary tax extensions by fixing the excise tax at USD 1.10 per underground ton and USD 0.55 per surface ton [6]. Predictable funding sustains medical benefit payments, which cover diagnostic testing, prescriptions and oxygen for eligible miners.

### AI-Assisted Radiograph and CT Reading

The ILO's 2022 revision of its radiograph classification guidelines formally accommodates digital images, removing a barrier to software-supported reading [8]. Imaging vendors now bundle deep-learning tools that flag opacities and grade profusion, shortening turnaround for NIOSH B Reader workflows. A shortage of certified B Readers, which numbered fewer than 200 active readers in the US in recent NIOSH listings, makes automation commercially attractive [2].

### Growth of Home Oxygen and Portable Concentrators

Long-term oxygen therapy is the mainstay for hypoxaemic patients with advanced pneumoconiosis. Portable concentrator makers report rising patient-direct and rental volumes, with Inogen citing growth in its rental and direct-to-consumer channels in 2024 [18]. ResMed's expanding respiratory care and software portfolio also points to more monitoring of chronic lung patients at home [21]. The shift moves spend from inpatient stays to recurring equipment and service contracts.

## Restraints

## Restraints Impact Analysis

Negative impact estimates for the Black Lung Disease Market are directional and overlap with each other. They indicate the relative drag each factor places on growth and should not be summed to derive a net rate.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Absence of curative or disease-modifying therapy | -1.1% | Global | Long-term (≥4 yr) |   |
| Declining coal employment in mature economies | -0.8% | North America, Europe | Long-term (≥4 yr) | [5][10] |
| Disruption to federal surveillance capacity | -0.5% | United States | Short-term (≤2 yr) | [25] |
| Under-diagnosis and weak reporting in emerging markets | -0.6% | Asia-Pacific, Africa, South America | Medium-term (2–4 yr) | [15][23] |
| Enforcement delays for new exposure rules | -0.4% | United States | Short-term (≤2 yr) | [1] |

### Absence of Curative or Disease-Modifying Therapy

No therapy reverses coal dust fibrosis. Clinical reviews describe management as symptomatic, relying on bronchodilators, oxygen, rehabilitation and, for end-stage cases, transplantation. Without a high-value drug class, treatment revenue grows with patient volume rather than price, which caps upside and limits pharmaceutical investment in disease-specific trials.

### Declining Coal Employment in Mature Economies

As of late 2026, the US Bureau of Labor Statistics reported that the number of coal miners in the United States had decreased to approximately 38,000, a significant decrease from the apex of 178,000 in 1985. In accordance with the EU's decarbonization objectives, the extraction of hard coal in Europe has been phased out. The demand for diagnostic and equipment services is shifted toward an aging cohort of retired miners, as a result of the reduction in routine surveillance enrollments due to the shrinking active workforce, rather than new market entrants.

### Disruption to Federal Surveillance Capacity

Department of Health and Human Services (HHS) administrative actions issued reduction-in-force notices in April 2025, which impacted approximately 90% of the National Institute for Occupational Safety and Health (NIOSH) workforce. The disruption underscored the systemic reliance on a single federal program for mobile X-ray and spirometry screening, resulting in budgetary uncertainty through 2026, despite the fact that congressional pressure resulted in staff reinstatements later in 2025.

### Under-Diagnosis and Weak Reporting in Emerging Markets

India's mining regulator records only a small number of pneumoconiosis cases annually relative to its large mining workforce, a gap researchers attribute to limited radiology access and informal employment [15]. South Africa's Tshiamiso Trust process shows how compensation claims stall without documented diagnoses [23]. Poor case capture keeps addressable demand below the true disease burden.

### Enforcement Delays for New Exposure Rules

MSHA paused enforcement of the silica rule at coal mines for several months in 2025, and further delays have been discussed for metal and non-metal operations [1]. Postponements push back sampling-linked medical examinations and the associated purchasing of imaging and lung-function services, shifting expected revenue into later forecast years.

## Opportunities

## Black Lung Disease Market Opportunities

### Integrated Surveillance-as-a-Service for Mine Operators

Despite the fact that China, India, and Indonesia collectively employ millions of coal workers, the radiology capacity in mining districts remains deficient. In the broader pneumoconiosis and occupational lung disease landscape, Asia-Pacific holds a 34.4% market share. Portable digital X-ray units equipped with AI triage have the potential to address this imbalance at a lower cost per scan than hospital referrals. Vendors with local service networks are favored by the tender-based demand that is generated by governments that enforce occupational health examinations.

### Screening Build-Out in Asia-Pacific Coal Regions

China, India and Indonesia together employ millions of coal workers, yet radiology capacity in mining districts remains thin. Portable digital X-ray units with AI triage could close this gap at lower cost per scan than hospital referral. Governments enforcing occupational health examinations create tender-based demand that favours vendors with local service networks.

### Real-World Data and Registry Monetisation

Decades of standardised ILO-classified images and linked spirometry from surveillance programs form a rare longitudinal dataset. De-identified registries could support antifibrotic trial design, AI model training, and insurer risk modelling. Licensing such data, under appropriate governance, offers a high-margin revenue line that capitalizes on a global antifibrotic drugs market valued at approximately USD 8 billion.

### Repurposing Antifibrotic Drugs

Nintedanib already carries an indication for progressive fibrosing interstitial lung diseases, and Boehringer Ingelheim's nerandomilast received US approval for idiopathic pulmonary fibrosis in 2025 [17]. Trials targeting pneumoconiosis-related progressive fibrosis would open a premium therapy tier in a market currently limited to symptomatic care.

### Home-Based Pulmonary Rehabilitation and Remote Monitoring

Former miners often live far from specialist centres. Tele-rehabilitation programs, home oximetry, and concentrator telemetry allow clinicians to manage advanced patients remotely and detect exacerbations earlier. Home-care settings within respiratory and pulmonary therapeutic markets are scaling rapidly at an 8.78% CAGR, making this commercially viable for clinics serving rural areas like Appalachia.

## Future Outlook

## Black Lung Disease Market Future Outlook

### AI-Led Image Interpretation Becomes Standard

The global antifibrotic drugs market is currently valued at USD 8.2 billion. It is expected to grow to $15.7 billion by 2033 at a compound annual growth rate (CAGR) of 8.3%, driven by the sustained pharmaceutical investments that have been stimulated by progressive fibrosing lung diseases. Treatment spending per patient is anticipated to increase considerably as established agents such as nintedanib (holding a 35.9% market share) and pirfenidone (30.1% market share) expand through [clinical trials](https://www.marketresearchfuture.com/reports/clinical-trials-market-7787) targeting occupational pneumoconiosis.

### Coal Transition Reshapes Patient Geography

Despite the ongoing decline in coal demand in advanced Western economies, global consumption remains high. The International Energy Agency (IEA) predicts that global coal demand will reach 8.94 billion tons, propelled by regional increases in developing Asian markets. Patient pools are relocating to Asia, while mature markets concentrate on the elderly former miners. Suppliers necessitate dual strategies: chronic respiratory care in the West and mass screening infrastructure in the East.

### Fibrosis Drug Pipeline Matures

Progressive fibrosing lung disease has drawn sustained pharmaceutical investment, with nintedanib, pirfenidone and nerandomilast establishing an antifibrotic class [17]. If outcome trials extend these agents to pneumoconiosis, treatment spending per patient could climb meaningfully after 2030, changing the revenue mix within the treatment component.

### ESG Reporting Raises Occupational Health Visibility

Investors increasingly expect mining companies to disclose worker health metrics under sustainability frameworks such as the GRI 403 occupational health standard [24]. Transparent reporting of respiratory surveillance coverage pressures operators to fund screening beyond legal minimums, supporting steady procurement of diagnostic services.

## Segment Insights

## Black Lung Disease Market Segmentation

### By Disease Type

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Simple Coal Workers’ Pneumoconiosis | 5.9% CAGR (2026–2035) | Broader screening and early AI-flagged detection |
| Complicated Coal Workers’ Pneumoconiosis | 41.2% share | High imaging and treatment intensity |
| Progressive Massive Fibrosis | USD 0.55 Billion | Transplant evaluation, oxygen and rehabilitation needs |

Complicated Coal Workers’ Pneumoconiosis holds the largest share of the Black Lung Disease Market because advanced fibrosis drives repeated CT imaging, specialist visits and long-term oxygen. Progressive Massive Fibrosis carries the highest per-patient cost, including transplant workups. Simple Coal Workers’ Pneumoconiosis grows fastest, but much of that growth reflects better case discovery through expanded screening rather than a rise in severe clinical burden.

### By Component

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Diagnostic Method | USD 1.10 Billion | Surveillance mandates and compensation evaluations |
| – Chest X-Ray | 58.0% share of diagnostic method | ILO-classified surveillance radiographs |
| – CT Scan | 6.1% CAGR (2026–2035) | Detection of early nodules and PMF staging |
| – Pulmonary Function Test | USD 0.22 Billion | Spirometry in periodic examinations |
| – Other Diagnostic Methods | 4.4% share of diagnostic methods | Biomarkers, DLCO and biopsy |
| Treatment Type | 55.1% share | Medication, oxygen therapy and transplantation |

Treatment Type leads the Black Lung Disease Market and also posts the fastest component growth, supported by bronchodilators, inhaled corticosteroids, long-term oxygen and a small but costly lung transplant tier. Within Diagnostic Method, Chest X-Ray remains the backbone of worker surveillance, while CT Scan grows fastest as clinicians use it to confirm and stage disease that radiographs miss. Pulmonary Function Test volumes track periodic examinations closely.

### By End-user

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 43.9% share | Inpatient management and multidisciplinary review |
| Specialty Clinics | USD 0.52 Billion | Long-term follow-up of working miners |
| Diagnostic Laboratories | 6.3% CAGR (2026–2035) | Decentralised spirometry and imaging reads |
| Other End-Users | 4.2% CAGR (2026–2035) | Mobile screening units and occupational health providers |

Hospitals anchor the Black Lung Disease Market with the largest end-user share because advanced cases require inpatient care, transplant evaluation and specialist pulmonology. Diagnostic Laboratories grow fastest as spirometry, HRCT interpretation, and biomarker testing shift closer to occupational health pathways. Specialty Clinics hold durable outpatient relationships, especially with miners under Part 90 transfer rights who need monitoring while working in reduced-dust settings.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.5% share | Federal surveillance, benefits-funded care, PMF management |
| Europe | 22.0% share | Occupational-disease registries, silica directive compliance |
| Asia-Pacific | 7.1% CAGR (2026–2035) | Mandatory worker screening, hospital radiology expansion |
| South America | USD 0.14 Billion | Brazil coal-belt surveillance, Andean mining health rules |
| Middle East and Africa | 7.0% share | Compensation frameworks, mine health examinations |
| Total | USD 2.46 Billion | – |

The Black Lung Disease Market spans five regions with distinct demand profiles: benefits-driven care in North America, regulation-driven surveillance in Europe and volume-driven screening growth in Asia-Pacific.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 89.0% share of region | NIOSH surveillance, Black Lung Benefits Program |
| Canada | 5.2% CAGR (2026–2035) | Provincial workers' compensation screening |
| Mexico | USD 0.03 Billion | Coahuila coal basin occupational health |

The US dominates regional revenue because federal law guarantees chest X-ray examinations for underground coal miners and funds medical benefits for approved claimants [2][5]. Central Appalachia, covering Kentucky, Virginia and West Virginia, concentrates PMF cases and transplant referrals [3]. Canada's demand comes from British Columbia and Alberta coal operations under provincial compensation boards, while Mexico's Coahuila region carries a documented history of mine safety deficits.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 21.0% share of region | Legacy Ruhr and Saar miner follow-up |
| UK | USD 0.08 Billion | Industrial Injuries Disablement Benefit cases |
| France | 4.1% CAGR (2026–2035) | Occupational disease tables for pneumoconiosis |
| Italy | 8.5% share of region | Silica exposure in quarrying and construction |
| Spain | USD 0.04 Billion | Asturias mining cohort and engineered stone silicosis |
| Nordic Countries | 3.8% CAGR (2026–2035) | Strong occupational registries |
| Russia | 17.5% share of region | Kuzbass coal workforce screening |
| Rest of Europe | USD 0.08 Billion | Poland's Silesian mining health programs |

European demand rests largely on legacy cohorts of former miners and on silica control. Directive (EU) 2017/2398 added respirable crystalline silica dust generated by work processes to the Carcinogens and Mutagens Directive, with a binding limit of 0.1 mg/m³, driving health surveillance across mining and construction [22]. Germany and the UK maintain long-standing compensation registries, while Russia's Kuzbass basin and Poland's Silesia keep active coal workforces under periodic examination.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 52.0% share of region | Mandatory occupational health examinations |
| India | 8.4% CAGR (2026–2035) | Coal India expansion and DGMS medical rules |
| Japan | USD 0.04 Billion | Legacy pneumoconiosis compensation |
| South Korea | 6.0% share of region | Pneumoconiosis relief act for former miners |
| ASEAN | 7.9% CAGR (2026–2035) | Indonesian coal output growth |
| Rest of Asia-Pacific | USD 0.07 Billion | Australian coal mine dust lung disease screening |

Asia-Pacific growth in the Black Lung Disease Market stems from the world's largest coal workforces. China reports pneumoconiosis as its leading occupational disease and requires examinations before, during and after dust-exposed employment. India's coal output passed one billion tonnes in fiscal 2024–25, expanding the exposed population faster than radiology capacity [15]. Queensland's post-2015 reforms, prompted by a cluster of re-identified cases, raised screening standards across Australian coal mines [13].

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 46.0% share of region | Santa Catarina coal region health monitoring |
| Argentina | USD 0.02 Billion | Río Turbio mining workforce |
| Rest of South America | 5.8% CAGR (2026–2035) | Colombian coal exports and occupational rules |

South American revenue is modest but rising as mining governments formalise occupational health. Colombia, a leading coal exporter, sits within the Rest of South America group and drives much of the regional upside through employer-funded examinations. Brazil's southern coal belt maintains public-health surveillance through its unified health system, while Argentina's demand is concentrated in Patagonian state-run mining.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | USD 0.02 Billion | Mining expansion under Vision 2030 |
| UAE | 7.5% share of region | Private pulmonary centres |
| South Africa | 55.0% share of region | Mine worker compensation and Tshiamiso Trust |
| Egypt | 6.2% CAGR (2026–2035) | Quarrying silica exposure |
| Rest of MEA | USD 0.03 Billion | Zimbabwe and Mozambique coal operations |

South Africa accounts for the bulk of regional revenue through statutory benefit medical examinations and the Tshiamiso Trust, which settles silicosis and tuberculosis claims for former gold miners and processes thousands of medical assessments [23]. Mining expansion in Saudi Arabia adds new occupational health obligations, while Mozambique's Moatize coal basin creates emerging screening demand.

## Competitive Benchmarking

## Competitive Benchmarking

The Black Lung Disease Market is moderately concentrated, with an estimated HHI of 900–1,100. The top five suppliers account for roughly 38–45% of revenue, split between respiratory drug makers and imaging and oxygen equipment providers. Fragmentation persists in services, where regional hospitals, black lung clinics and independent laboratories capture most diagnostic and follow-up spending.

| Company | Est. Revenue Share Range | Key Offerings for Black Lung Disease Market | Strategic Positioning |
| --- | --- | --- | --- |
| Boehringer Ingelheim | ~8–11% | Antifibrotics, inhaled bronchodilators | Leader in fibrosing lung disease therapy |
| GSK plc | ~6–9% | Inhaled corticosteroid and bronchodilator combinations | Broad respiratory portfolio |
| AstraZeneca | ~6–8% | Triple-therapy inhalers | Respiratory franchise with chronic care focus |
| F. Hoffmann-La Roche | ~4–6% | Pirfenidone | Antifibrotic presence |
| Novartis | ~3–5% | Long-acting bronchodilators | Selective respiratory exposure |
| Koninklijke Philips | ~5–7% | Digital radiography, CT, oxygen concentrators | Imaging-plus-home care, rebuilding post-recall |
| GE HealthCare | ~5–7% | Digital X-ray, CT, AI reading tools | Imaging scale and AI integration |
| Siemens Healthineers | ~4–6% | Low-dose CT, digital radiography | Premium imaging installed base |
| ResMed | ~2–4% | Respiratory devices, home monitoring software | Connected home respiratory care |
| Inogen | ~2–3% | Portable oxygen concentrators | Patient-direct and rental channels |
| Teva Pharmaceutical | ~2–4% | Generic inhalers | Low-cost maintenance therapy |

## Recent News & Developments

## Recent News & Developments

- Inogen (January 2023): Launched the Rove 4 portable oxygen concentrator in the US, adding a lighter option for ambulatory patients with chronic lung disease [18]
- MSHA (April 2024): Published its final rule lowering the respirable crystalline silica limit to 50 µg/m³ and requiring medical surveillance for metal and non-metal miners [1]
- Philips (April 2024): Entered a consent decree with the US DOJ and FDA governing Respironics sleep and respiratory device operations, reshaping its US home respiratory business [16]
- HHS/NIOSH (April 2025): Workforce reductions affected the Respiratory Health Division and temporarily disrupted coal miner health surveillance services [25]
- MSHA (April 2025): Paused enforcement of the silica rule at coal mines for four months to allow operators to secure sampling capacity [1]
- Boehringer Ingelheim (October 2025): Received US FDA approval for nerandomilast in idiopathic pulmonary fibrosis, widening the antifibrotic class relevant to fibrosing pneumoconiosis research [17]
- Coal India (2025): Reported coal output above one billion tonnes for fiscal 2024–25, expanding the exposed workforce subject to periodic medical examination [15]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Diagnosis and treatment of coal workers' pneumoconiosis and progressive massive fibrosis, covering imaging, lung function testing, medication, oxygen therapy and transplantation across hospitals, clinics and laboratories |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 2.46 Billion |
| Market Size in 2035 | USD 4.14 Billion |
| CAGR (2026–2035) | 5.48% |
| Fastest Growing Segments | Diagnostic Laboratories (6.3% CAGR); CT Scan (6.1% CAGR); Simple Coal Workers’ Pneumoconiosis (5.9% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Boehringer Ingelheim, GSK plc, AstraZeneca, F. Hoffmann-La Roche, Novartis, Koninklijke Philips, GE HealthCare, Siemens Healthineers, ResMed, Inogen, Teva Pharmaceutical |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: Which buyers make the largest purchasing decisions in the Black Lung Disease Market?**
A: In the Black Lung Disease Market, federal surveillance programs, black lung clinics funded through HRSA grants and mine operators' occupational health contractors drive most diagnostic procurement. Oxygen and medication spending flows mainly through benefits payers and Medicare [5].

**Q: How do compensation rules affect diagnostic demand in the Black Lung Disease Market?**
A: Benefit claims in the Black Lung Disease Market require standardised ILO-classified radiographs, spirometry and arterial blood gas tests. Each claim therefore generates a defined bundle of reimbursable tests, regardless of whether the miner is ultimately awarded benefits [5][8].

**Q: What should procurement teams check before buying AI chest-reading software?**
A: Confirm regulatory clearance, validation against B Reader classifications and DICOM integration with existing PACS. Tools trained mainly on tuberculosis or general nodules may underperform on small rounded opacities typical of coal dust exposure [8].

**Q: How does silicosis from engineered stone relate to the Black Lung Disease Market?**
A: Engineered stone silicosis is adjacent to the Black Lung Disease Market and shares imaging, spirometry and oxygen pathways with coal-related disease. Australia banned engineered stone from July 2024, and screening infrastructure built for stonemasons can serve both patient groups [13].

**Q: Is lung transplantation a meaningful revenue pool?**
A: Volumes are small, but each transplant episode carries very high cost, including evaluation, surgery and lifelong immunosuppression. Coal miners with PMF now represent a growing share of occupational transplant referrals in Appalachia [3].

**Q: What role does pulmonary rehabilitation play in long-term care?**
A: Rehabilitation improves exercise capacity and quality of life in pneumoconiosis patients, though it does not halt fibrosis. Programs delivered through black lung clinics are often bundled with benefits counselling [4].

**Q: Which investment risk deserves the closest attention through 2035?**
A: Policy volatility is the main risk for the Black Lung Disease Market. Changes to federal surveillance staffing or exposure-rule enforcement can shift demand timing by several years, as 2025 showed [1][25].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/black-lung-disease-market-5711*
